Welcome reception

Introduction & Meeting Objectives
John Gribben

Session 1:  T-cell Leukemia/Lymphoma
Chairs: Laurence de Leval & Francine Foss

 

Special Lecture: T-cell Leukemia/Lymphoma

• Pre-clinical models for precision therapy in TCLs; Francois Lemonnier
• Epidemiology and novel biomarkers of relapse refractory T-cell lymphoma; Salvia Jain
• Pathology classification and recent advances, if we want to put a focus on CTCL; TBC
• Aggressive T-cell lymphoma in refractory patients; Francine Foss
• Epigenetic therapies in PTCLs; TBC
• Evolving therapies in TCL (CAR-T, BsAbs, VALEMETOSTAT & VALENTINE); Pier Luigi Zinzani

 

Roundtable Discussion

Break

Session 2: Session II:  MCL
Chairs: Stephen Ansell & TBC

 

• Evolution of  Mantle Cell lymphoma(s):  From Conception to the Current Reality; Elaine Jaffa 
• Frontline therapy for MCL – which patient needs which initial regimen?; TBC
• Consolidation after frontline therapy – is autologous stem cell transplantation for MCL a thing of the past?; TBC
• How to use MRD to manage MCL; TBC
• Small molecule inhibitors for relapsed MCL – one at a time or all together? Tycel Phillips

 

Panel Discussion: Remaining gaps and perspectives

Session 3: Keynote address
Chair & Introduction: John Gribben

Keynote: Capturing and targeting the molecular heterogeneity in diffuse large B-cell lymphoma; TBC

 

Panel Discussion

Lunch

Session 4: Novel therapies I
Chairs: Jason Westin & TBC

 

Industry Panel Discussion: Simon Rule

• Harmonized criteria for reporting of imaging in CRFs; an industry perspective; TBC
• ODAC regulatory perspectives on CRFs in Lymphoma; TBC

 

Roundtable discussion

 

 

McAbs and ADC Combinations:

• Tafasitamab combinations, TBC
• Zilovertamab combinations; TBC
• Loncastuximab combinations; Juan Pablo Alderuccio
• Polatuzumab combinations; Gilles Salles
• What’s next in Mab’s and ADC’s?; TBC
• Finding the right combination- The value and limits of preclinical studies; TBC

 

Roundtable Discussion

Break

Session 5: Special Topic: Hodgkin’s Lymphoma
Chairs: TBC

 

• Early stage HL; TBC
• Adv stage HL; TBC
• 2nd Line treatment; TBC
• Beyond 2nd line; Alex Herrera
• Elderly HL; TBC
• 1st Line AYA; TBC

 

Panel Discussion

Day 1 Wrap Up

Session 6: Bispecific antibodies in 1st and 2nd line treatment of FL and DLBLC   
Chairs: Martin Hutchings & TBC

 

CD3/CD20 bispecifics in early lines of treatment in FL and LBCL

• Mosunetuzumab; TBC
• Epcoritamab combinations; Lorenzo Falchi
• Glofitamab combinations; Martin Hutchings
• Plamotamab; combinations; Tycel Phillips
• Odronextamab; TBC
• AZD0486; TBC

 

Roundtable Discussion

 

Bispecific and trispecifics with other formats and targets

• Imvotamab; TBC
• TNB 486; TBC
• Future perspectives with bi-and trispecific antibodies; Jason Westin

 

Roundtable Discussion: Future Directions 

Break

Session 7: Novel Therapies
Chairs: Laurie Sehn & Alexey Danilov

 

BTK Inhibitors combinations:

• Zanubrutinib combinations; Pier Luigi Zinzani
• Acalabrutinib combinations; Krish Patel 
• Pirtobrutinib combinations; Michael Wang
• Ibrutinib; Chris Flowers

 

 

Lunch

BTK Degraders:

• BGB-16673; TBC
• NX-2127 and NX5948; Alexey Danilov

BCL-2 inhibitors:

• Sonrotoclax; TBC
• What’s next in targeted therapy?; TBC
• Using genomics to guide therapeutic choice; TBC

 

Roundtable Discussion

 

Session 8: Expanding the CAR platform for NHL
Chairs: David Maloney & TBC

 

Real World Data: 

• Liso-cel for DLBCL; Jeremy Abramson
• Axi-cel; Sattva Neelapu
• Tis-a-cel, Liso-cel & Axi-cel in FL; TBC
• Future perspectives – where do we go from here?; Jason Westin

e-break

• Molecular disease monitoring in patients with R/R B-Cell Lymphoma; TBC
• Rapcabtagene; TBC
• CD20 CAR-T; Mazyar Shadman
• Multi-targeted CARs; TBC
• Allogeneic CAR-T cells: Is there a strategy moving forward?; TBC
• CB-010 (anti-CD19 CAR-T); TBC

 

Roundtable Discussion: CAR-T in the real-World Setting

Final Meeting Summary and Conclusions
Chairs: iwNHL Committee